Coronary Artery Bypass Grafting Clinical Trial
Official title:
Quality Measurement and Improvement Study of Surgical Coronary Revascularization: Secondary Prevention
The investigators have identified underuse of secondary prevention medications at discharge of patients underwent coronary artery bypass grafting (CABG) in China. The aim of this study is to develop series of quality improvement strategies focusing on secondary prevention medications for patients underwent CABG, and to evaluate their effectiveness and safety via a hospital-level cluster randomized clinical trial. The investigators established a network of 60 hospitals which have participated into Chinese Cardiovascular Surgery Registry and submitted 50 or more CABG surgeries already. The participating sites will be divided into intervention and control groups in a 1:1 ratio. The intervention group will undertake intervention of quality improvement strategies, while the control group will maintain the routine practice pattern. All hospitals will consecutively enroll and submit data of CABG during the enrollment period, estimated for 6 months. The prescribing rates of angiotensin converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), beta-blockers, statins and aspirins will be compared between 2 groups.
The investigators have identified underuse of secondary prevention medications at discharge
of patients underwent coronary artery bypass grafting (CABG) in China. The aim of this study
is to develop series of quality improvement strategies focusing on secondary prevention
medications for patients underwent CABG, and to evaluate their effectiveness and safety via a
hospital-level cluster randomized clinical trial. The investigators established a network of
60 hospitals which have participated into Chinese Cardiovascular Surgery Registry and
submitted 50 or more CABG surgeries already. The participating sites will be divided into
intervention and control groups in a 1:1 ratio. The intervention group will undertake
intervention of quality improvement strategies, while the control group will maintain the
routine practice pattern. All hospitals will consecutively enroll and submit data of CABG
during the enrollment period of estimated 6 months. The prescription rates of ACEI, ARB,
beta-blockers, statins and aspirins will be compared between 2 groups.
Before the enrollment period, the investigators have developed series of quality improvement
strategies focusing on secondary prevention medications for patients underwent CABG,
including training with guidelines of secondary preventions, determining improvement goals
with participating sites, intervention tools (workflow posters and cards, checklists to
inform the use of secondary prevention medications) and periodical quality feedback reports.
In the enrollment period, participating hospitals will be divided into intervention and
control groups in a 1:1 ratio using minimization allocation.
The investigators will collect data on the prescription rates from central medical record
abstraction, case report forms submitted by participating sites and checklists submitted by
intervention groups.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04566497 -
Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up.
|
N/A | |
Completed |
NCT01850082 -
Randomized Endo-Vein Graft Prospective
|
N/A | |
Not yet recruiting |
NCT04657835 -
Assessment of Atrial Cardiomyopathy Using MRI as a Predictor of Cardiac Post-Operative Atrial Fibrillation After Cardiac Surgery.
|
N/A | |
Completed |
NCT02889562 -
Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation
|
Phase 2/Phase 3 | |
Completed |
NCT01378221 -
VItamin D Metabolism in SEnescent Cardiac Surgery Patients
|
N/A | |
Completed |
NCT01528514 -
Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study
|
N/A | |
Completed |
NCT00848796 -
Comparative Study of Two Brands of Heparin Already on the Market
|
N/A | |
Not yet recruiting |
NCT05552586 -
Melatonin Impact on the Outcomes of Myocardial Ischemia/Reperfusion Injury During Coronary Artery Bypass Grafting Surgery
|
N/A | |
Completed |
NCT00246740 -
Protection of the Heart With Doxycycline During Coronary Artery Bypass Grafting
|
Phase 2 | |
Completed |
NCT00420667 -
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
|
N/A | |
Recruiting |
NCT04197700 -
The PRESSURE CABG Cardiac Surgery Trial
|
N/A | |
Not yet recruiting |
NCT05835167 -
Complete Revascularization Via Inferior Part-sternotomy
|
N/A | |
Not yet recruiting |
NCT06326996 -
Thiamine Intervention and Coronary Artery Bypass Grafting
|
N/A | |
Not yet recruiting |
NCT02732574 -
Oscillating Positive Expiratory Pressure (OPEP) Therapy in High Risk Patients Following Cardiac Surgery
|
N/A | |
Completed |
NCT00903604 -
Pharmacokinetics of AP214 Acetate in Patients Undergoing Cardiac Surgery
|
Phase 2 | |
Completed |
NCT01182688 -
Prospective Review of Procalcitonin After Cardiac Surgery
|
N/A | |
Completed |
NCT02737215 -
Prevention of Atrial Fibrillation After Coronary Artery Bypass Grafting in Patients With Obstructive Sleep Apnea
|
N/A | |
Recruiting |
NCT03209414 -
Frailty Syndrome in Daily Practice of Interventional Cardiology Ward
|
||
Recruiting |
NCT05441358 -
Assessment of Platelet Function in Patients Undergoing Open Heart Surgery
|
||
Recruiting |
NCT02400125 -
China Cardiovascular Surgery Registry
|
N/A |